Tilray Brands (NASDAQ:TLRY) shares declined 4% in Wednesday morning trading, falling to around $6.20 after opening at $6.47. The drop came despite the company posting what it called a record Q3 result, leaving investors to weigh headline growth against a more complicated underlying story.
Tilray shares have lost 97% over five years, one of the steepest long-term declines among consumer-facing brands. Today’s move is relatively contained compared to prior earnings reactions, but the market’s message is consistent: revenue growth must translate into earnings before investors will reward the stock.
Three specific issues are driving skepticism this morning, and together they explain why even a record quarter has failed to shift investor sentiment.
Reason 1: The EPS Miss Overshadows the Revenue Beat
Tilray reported Q3 FY2026 net revenue of $206.7 million, beating the consensus estimate of $201.3 million. That sounds encouraging on the surface. Yet, Tilray’s adjusted EPS came in at a loss of $0.24, significantly worse than the $0.14 loss analysts had expected, a miss of 71.43%.
TD Cowen responded by cutting its TLRY stock price target from $10 to $7, even while maintaining its Buy rating. For a company that has spent years promising a credible path to profitability, missing EPS estimates by this margin reinforces the bear case that revenue growth is not yet translating into sustainable earnings.
Reason 2: Dilution Concerns and Share Price Destruction
The five-year chart for TLRY stock tells a painful story. A 97% share-price drawdown reflects more than sector headwinds. It reflects a pattern of shareholder dilution through equity issuances, debt-for-equity exchanges, and acquisitions.
The most recent example is the BrewDog acquisition, purchased for approximately $53 million; this brand was once valued at $2 billion at its peak. Adding to the legal picture, the Bob Marley estate recently sued Tilray for nearly $13 million in unpaid licensing fees, filed in Delaware Chancery Court. Until Tilray demonstrates it can grow without consistently diluting existing shareholders, the structural overhang will remain.
Reason 3: Cannabis Rescheduling Delays and an Unproven Beverage Pivot
Much of the long-term bull case for Tilray has rested on U.S. cannabis rescheduling, which would dramatically expand its addressable market. Regulatory progress, however, continues to move slowly, and that delay keeps a meaningful catalyst off the table for now. Meanwhile, Tilray’s beverage pivot, while strategically interesting, remains unproven at scale.
Tilray has acquired BrewDog and partnered with Carlsberg beginning in 2027. The company’s Shock Top brand just launched “High Voltage,” a 9.6% ABV double wheat beer. These are real moves, but none have yet demonstrated the revenue acceleration needed to offset cannabis sector headwinds. Until Tilray’s beverage segment generates meaningful profitability, investors will remain cautious.
The Bull Case Has Real Data Behind It
Granted, the bears don’t own the entire story. Tilray’s Q3 net loss of $25.2 million was a dramatic improvement from the $793.5 million loss in the prior year period. Canadian combined cannabis revenue grew 8%, and international cannabis revenue surged 73% year over year, a company record.
Moreover, Tilray’s management reaffirmed its FY2026 adjusted EBITDA guidance of $62 million to $72 million. This represents 13% to 31% growth versus FY2025.
Additionally, the analyst consensus price target for TLRY stock sits at $11.75, implying substantial upside from current levels if execution improves. Tilray CEO Irwin D. Simon asserted that the quarter demonstrated “the strength of our global strategy in action, delivering our strongest Q3 net revenue and gross profit to date.”
What to Watch
Tilray’s earnings call began at 8:30 a.m. EST this morning, so management’s commentary is now in the market. Investors should watch whether TLRY shares stabilize above $6.20 into the close, and whether any analyst commentary following the call shifts the consensus rating off its current “Hold” stance.
The next real test will be whether the beverage segment and international cannabis growth can begin closing the gap between Tilray’s revenue ambitions and its profitability reality. With negative free cash flow of $24.19M and an EPS miss of 71.43%, the burden of proof remains squarely on Tilray’s management to demonstrate that record revenue can translate into shareholder returns.
Top Gaining Stocks
Top Losing Stocks